Moar Graphene, brought to you by Nokia, Merck and others…

From the Merck article:

" Joint development agreement represents a promising step towards a highly selective and efficient next generation of bioelectronic therapies powered by graphene.

BARCELONA, Spain, July 08, 2021(BUSINESS WIRE)

INBRAIN Neuroelectronics, a company at the intersection of medtech, deeptech and digital health dedicated to developing the world’s first graphene-based intelligent neuroelectronic system, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company. The aim of the collaboration is to co-develop the next generation of graphene bioelectronic vagus nerve therapies targeting severe chronic diseases in Merck’s KGaA, Darmstadt, Germany therapeutic areas through INNERVIA Bioelectronics, a subsidiary of INBRAIN Neuroelectronics.

Bioelectronic devices have the capability to directly communicate with the nervous system. Recording nerve signals and combining them with other accessible physiological datasets will lead to a better understanding of disease conditions and enable personalized treatment regimens," said Robert Spoelgen, Head of Bioelectronics, Innovation Center of Merck KGaA, Darmstadt, Germany. "We are convinced that bioelectronic devices will play a significant role in the future therapeutic landscape.

….

Furthermore, neurostimulation devices are expected to become increasingly smart as a result of additional features such as continuous readouts, data analysis and data transmission"

https://archive.ph/cqmZR

https://graphene-flagship.eu/collaboration/our-partners/

>>14093688 (me) WTAF?

Jun 14, 2020

INBRAIN Neuroelectronics was established in 2019 with the mission of developing brain-implants based on graphene technology for application in patients with epilepsy, Parkinson’s, and other neuronal diseases. These smart devices, built around an innovative graphene electrode, will decode with high certainty neural signals from the brain and produce a therapeutic response adapted to the clinical condition of the specific patient.

The company is designing the least invasive and smartest neural interface that, powered by artificial intelligence and the use of Big Data, will have the ability to read and modulate brain activity, detect specific biomarkers, and trigger adaptive responses to deliver optimal results in personalised neurological therapies. So far, the technology has been validated in in-vitro and in-vivo biocompatibility and toxicity tests and has been successfully used to complete studies on small animals. Recently, INBRAIN began tests on large animals with the aim of ensuring that these graphene devices are safe as well as superior to current solutions based on metals such as platinum and iridium. The company also plans to start human studies soon.

https://www.graphene-info.com/inbrain-neuroelectronics-receives-funding-push-forward-development-graphene

https://archive.ph/eETEp

https://www.graphene-info.com/